Nuveen Asset Management LLC Has $31.14 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Nuveen Asset Management LLC cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 78.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 475,222 shares of the company's stock after selling 1,780,358 shares during the quarter. Nuveen Asset Management LLC's holdings in AstraZeneca were worth $31,137,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banque Transatlantique SA bought a new stake in shares of AstraZeneca during the 4th quarter valued at approximately $26,000. Albion Financial Group UT grew its holdings in shares of AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company's stock valued at $40,000 after purchasing an additional 248 shares during the last quarter. CoreCap Advisors LLC grew its holdings in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after purchasing an additional 155 shares during the last quarter. Golden State Wealth Management LLC bought a new stake in AstraZeneca during the 4th quarter worth approximately $55,000. Finally, Crews Bank & Trust bought a new stake in AstraZeneca during the 4th quarter worth approximately $55,000. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. BNP Paribas assumed coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price on the stock. Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating on the stock. Finally, UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $88.00.

AstraZeneca Trading Up 0.8%

Shares of NASDAQ AZN traded up $0.55 during midday trading on Tuesday, reaching $70.96. The stock had a trading volume of 4,459,225 shares, compared to its average volume of 5,181,264. The firm has a market cap of $220.07 billion, a price-to-earnings ratio of 31.40, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The company's 50 day moving average price is $69.54 and its 200 day moving average price is $69.57.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The company's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.06 EPS. As a group, sell-side analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.